Suggestions
Anarghya Vardhana
Recognized for Forbes 30 under 30 and involved in various significant roles across tech and investment sectors.
Anarghya Vardhana is a Partner at Maveron LLC, a venture capital firm based in San Francisco that specializes in early-stage consumer investments. She joined Maveron in November 2015, following a year at Rothenberg Ventures, where she launched a virtual reality accelerator and made seed investments in various startups.14
Education and Early Career
Vardhana graduated with honors from Stanford University, where she studied Science, Technology, and Society, focusing on Human Biology and Mathematics. Her career began at Google in 2010, where she worked on the AdWords Express product, contributing to its internationalization and localization efforts.234
Investment Focus
At Maveron, Anarghya Vardhana focuses on identifying and investing in companies that enhance health and wellness across large populations. Her investments span various sectors, including mental health, women's health, and healthcare platforms. Notable companies she has invested in include Alife, Caraway, and Goodbill.123
Achievements and Recognition
Vardhana has received several accolades, including being named in Forbes' "30 Under 30" list for venture capital. She is also a Kauffman Fellow and actively participates in diversity initiatives in the tech and venture capital sectors.234
Personal Background
Originally from the Pacific Northwest, Anarghya is passionate about technology's role in society and has a keen interest in addressing social issues related to women and marginalized communities. In her personal life, she is an avid marathon runner and practices Indian classical dance (Bharatanatyam).234
Highlights
I've been hearing a lot of chatter over the last couple days about Flo and the $1 billion valuation. In my opinion, this is yet another data-point that consumer is undervalued and underestimated. Flo built up a solid business - by my estimates in the hundreds of millions of dollars - with building a product that consumers not only want to use, but will continue to use in the years to come. Because it offers real value, they will pay $60 a year for it. I suspect anyone peeking under the hood would see not only a large TAM, but strong retention, an enviable LTV: CAC ratio and growing revenue. This is a big moment for consumer health and I'm here for it!
Who’s investing larger checks right now? I interviewed 8 of the most active growth investors for my handy guide for health-tech founders raising later-stage rounds. Enjoy!
Thank you to everyone who chatted with me, and Second Opinion Media for blazing the way with the seed guide 🙏
https://lnkd.in/gf_mWdjG
Billy Deitch, Daniel van den Bergh, Sarah Pinto Peyronel, Jocelyn Kinsey, Justin Kao, Kevin Spain, Fazeela Abdul Rashid, Cheryl Cheng, Teresa Lee
